Phaseline

Companies › EVD Pharmacy and Medical Company

EVD Pharmacy and Medical Company: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Cardiovascular; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MLC901 (NeuroAiD™ II)
Neuroprotective agent
–Phase 4StrokeSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07828210MLC901 (NeuroAiD™ II)Phase 4StrokeCardiovascularSep 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Trust Bio-sonics Liquidia Technologies Pulmovant EBI Anti Sepsis Agitated Solutions

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.